Aerosolized Aldesleukin in Treating Patients With Lung Metastases

Inclusion Criteria: * Patients with diagnosis of advanced cancer with lung metastases; patients with no prior therapy are eligible if there is no known superior alternative medical therapy; for phase Ib expansion cohort diagnosis of osteosarcoma, lung metastases will be required * Willing to comply with protocol therapy and required safety monitoring (self-report, pulse oximetry, remote spirometry, labs) * Creatinine =\< 2 x upper limit of normal (ULN) * Bilirubin =\< 5 x ULN * Aspartate aminotransferase (AST) =\< 5 x ULN * Forced vital capacity (FVC) \>= 50% predicted * Oxygen (O2) saturation at rest \>= 90% (off supplementary oxygen) * Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 for ages \>= 16 or Lansky play \>= 80% for ages =\< 15 * Patients must have recovered to =\< grade 1 toxicity (except alopecia and hearing loss) from any prior chemotherapy, other investigational therapy, hormonal, biological, targeted agents * No radiotherapy within 2 weeks: exception: patients may receive palliative low dose radiotherapy (30 Gy or less) for lesions outside the lung at the discretion of the treating physician; palliative radiotherapy could be given before aerosol treatment is started if necessary * Subjects have to be able to read and understand English * Patients with advanced cancer with resectable lung metastases * Patients with sarcoma, renal cell carcinoma, or melanoma or with known disease outside the lungs and/or thorax Exclusion Criteria: * Current…